ASCO 2017 - Acute Myeloid Leukemia

Results from a large database analysis revealed that a number of risk factors may independently contribute to overall survival in acute myeloid leukemia (AML).

Although idarubicin and cytarabine in combination with clofarabine or fludarabine have similar response profiles in patients with newly diagnosed acute myeloid leukemia (AML), differences in survival were seen between the 2 groups in younger patients.

Variability in surface antigen expression patterns correlated to different outcomes in patients with normal karyotype acute myeloid leukemia (AML).

Timed sequential administration of busulfan may represent a more efficacious approach to the treatment of patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Allogeneic stem-cell transplant was found to improve patient outcomes, regardless of age and induction regimen.

The PD-1 inhibitor nivolumab, in combination with azacytidine, may represent an effective treatment option for some patients with relapsed acute myeloid leukemia (AML).

Page 2 of 2
Results 11 - 16 of 16
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME